Mixed results seen in cardiovascular outcome trials of diabetes agents

PHILADELPHIA — Although some of the leading safety trials of newer anti-hyperglycemic drugs in patients with type 2 diabetes have shown reductions in cardiovascular risks, others have yielded mixed results, according to a presenter at the Heart in Diabetes Clinical Education Conference.
“Results of the EMPA-REG Outcome and LEADER trials represent a clinical breakthrough representing the first two antidiabetic interventions [empagliflozin (Jardiance, Boehringer Ingelheim), an SGLT2 inhibitor, and liraglutide (Victoza, Novo Nordisk), a GLP1 receptor agonist, respectively] to
Back to top button